Docetaxel and Carboplatin Combination Chemotherapy against Persistent or Recurrent Ovarian Cancer as 2nd or more line Chemotherapy.
- Author:
Young Hwan KIM
1
;
Hong Cheun SHIN
;
Sun Nie AHN
;
Chun June LEE
;
Won Gyu KIM
Author Information
1. Department of Obstetrics and Gynecology, College of Medicine, Kosin University, Busan, Korea.
- Publication Type:Original Article
- Keywords:
Docetaxel;
Carboplatin;
Recurrent or persistent ovarian cancer
- MeSH:
Bone Marrow;
Carboplatin*;
Drug Therapy*;
Drug Therapy, Combination*;
Humans;
Ovarian Neoplasms*;
Premedication
- From:Korean Journal of Obstetrics and Gynecology
2004;47(11):2123-2130
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVE: We evaluated the effects and toxicities of docetaxel-carboplatin combination chemotherapy against recurrent or persistent ovarian cancer who were previously heavily treated with one or more lines of chemotherapy. METHODS: Sixteen patients with a recurrent or persistent ovarian cancer, previously received first or more line chemotherapy, had been treated with docetaxel-carboplatin combination chemotherapy at Kosin Medical Center from December 2001 to May 2003. The docetaxel-carboplatin combination chemotherapy consists of docetaxel 75 mg/m2 and carboplatin 450 mg/m2 given i.v. every 3-4 weeks. The response of patients was evaluated with the tumor marker (serum CA-125) and imaging studies (ultrasonogram, CT, MRI). The toxicities were defined according to the WHO toxicity criteria. RESULTS: The overall response rate was 50% (8/16). Eight patients were evaluable for response by WHO criteria. The response rate by WHO criteria was 37.5% (3/8). In detail, complete response was 12.5%, partial response was 25%, stable disease was 37.5% and progressive disease was 25%. The serologic CA-125 response rate was 50% (8/16), in detail serologic partial response was 50%, and serologic stable disease was 31% and serologic progressive disease was 19%. The median response duration was 10 months (3 to 17 months), the median time to response was 1 month (1/2 to 2 months) and the median time to re-progression was 5 months (3 to 7 months). The most common toxicity was gastrointestinal toxicity and the bone marrow suppression was proved as a most serious side effect. CONCLUSION: The docetaxel-carboplatin chemotherapy as a 2nd or more lines regimen against heavily pre-treated recurrent or persistent ovarian cancer is considerable but was associated significant gastrointestinal and bone marrow side effects. Routine premedication is recommended.
